Relapsed or Refractory Acute Leukemia - Healing Genes

Relapsed or Refractory Acute Leukemia

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data

Phase N/A

Doctors at the Fred Hutchinson University of Washington Cancer Consortium are assessing the impact of a new method for screening leukemias in order to recommend custom chemotherapy treatment regimens. This new method tests many different drugs individually or in combination that kill leukemia cells, and includes genetic assessments of the tumor’s antigens for targeting. It is called high throughput drug sensitivity assay. Patients with acute leukemia that has returned after a period of improvement or does not respond to treatment may be eligible to be assayed and then follow the treatment recommendations. If they do, their clinical response to the recommended treatment will be followed as well.

This assay required leukemia cells to be taken from blood or bone marrow. After assay and completion of the chemotherapy recommended, patients are followed up at 2-4 weeks for response, and then every 3 months for 2 years for duration of response and survival.


  • Be 3 years of age or older
  • Have a diagnosis of acute leukemia that has
    • Relapsed after or refractory to prior treatment with at least two regimens or lines of treatment
    • Prior failure of at least one regimen or line of treatment, with poor cytogenetic or other risk factors, and ineligible for other clinical trials
  • Life expectancy of > 100 days


  1. Screening to confirm acceptance to the study.
  2. Leukapheresis or bone marrow collection (both outpatient procedures)
  3. The leukemia cells from step (2) will be assayed for sensitivity to individual drugs and drug combination and by gene sequencing.
  4. Receive personalized chemotherapy.
  5. Patients are followed up at 2-4 weeks for response, and then every 3 months for 2 years for duration of response and survival.

Trials will take place at the Fred Hutchinson/University of Washington Cancer Consortium in Seattle, WA. Map.

Pamela S. Becker  |  206-616-1589  |  [email protected]
University of Washington
National Cancer Institute (NCI)
Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader